News | April 10, 2013

Heart Surgery Increases Death Risk for Cancer Survivors who had Radiation Therapy

American Heart Association journal report explains greater risk


April 10, 2013 — Cancer survivors who had chest radiation are nearly twice as likely to die in the years after having major heart surgery as similar patients who didn't have radiation, according to research in the American Heart Association journal Circulation.

Chest radiation to kill or shrink breast cancer, Hodgkin's lymphoma and other cancers increases survivors' risk for major heart disease years — even decades — after radiation therapy.

"While radiation treatments done on children and adults in the late 1960s, '70s and '80s played an important role in cancer survival, the treatment often takes a toll on the heart," said Milind Desai, M.D., the study’s author and associate professor of medicine at the Cleveland Clinic in Ohio. "Survivors are at greater risk than people who do not have radiation to develop progressive coronary artery disease, aggressive valvular disease, as well as pericardial diseases, which affect the heart's surrounding structures. These conditions often require major cardiac surgery."

The study is the largest on how prior radiation affects long-term results from major heart surgery.

Researchers reviewed 173 patients who had radiation treatment for cancer an average 18 years before needing heart surgery. They followed the heart surgery patients an average 7.6 years and compared them to 305 patients undergoing similar heart surgeries who didn't have radiation therapy.

"These are major open-heart procedures, including valve or bypass procedures, and a vast majority had multiple simultaneous procedures, for example, multiple valve surgeries or valve plus bypass," said Desai. "About a quarter of the patients had redo surgeries, which puts them at even higher risk than those having the initial procedures."

Radiation patients had similar pre-surgical risk scores as non-radiated patients. Typically, preoperative risk scores help determine how patients will fare after surgery.

Patients had similar results in the first 30 days after major cardiac surgery regardless of their prior radiation status. However, during an average 7.6 years of follow-up, 55 percent of patients in the radiation group died, compared to 28 percent in the non-radiation group.

"These findings tell us that if you had radiation, your likelihood of dying after major cardiac surgery is high," said Desai. "That's despite going into the surgery with a relatively low risk score. In patients who have had prior thoracic radiation, we need to develop better strategies of identifying appropriate patients that would benefit from surgical intervention. Alternatively, some patients might be better suited for percutaneous procedures."

For more information: www.heart.org


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now